National Cancer Institute

The National Cancer Institute (NCI) coordinates the United

States National Cancer Program and is part of the National
National Cancer Institute
Institutes of Health (NIH), which is one of eleven agencies that are (NCI)
part of the U.S. Department of Health and Human Services. The
NCI conducts and supports research, training, health information
dissemination, and other activities related to the causes, prevention,
diagnosis, and treatment of cancer; the supportive care of cancer
Agency overview
patients and their families; and cancer survivorship.
Formed August 5, 1937
NCI is the oldest and has the largest budget and research program
Jurisdiction Federal
of the 27 institutes and centers of the NIH ($6.9 billion in 2020).[6]
government of the
It fulfills the majority of its mission via an extramural program that
United States
provides grants for cancer research. Additionally, the National
Cancer Institute has intramural research programs in Bethesda, Headquarters Office of the
Maryland, and at the Frederick National Laboratory for Cancer Director,
Research[7] at Fort Detrick in Frederick, Maryland. The NCI 31 Center Drive,
receives more than US$5 billion in funding each year.[8] Building 31,
Bethesda,
The NCI supports a nationwide network of 71 NCI-designated
Maryland,
Cancer Centers with a dedicated focus on cancer research and
20814
treatment[9] and maintains the National Clinical Trials
Network.[10] Agency Monica Bertagnolli,
executive Director

History Parent United States

department Department of
Health and Human
Timeline Services

August 5, 1937: President Franklin D. Roosevelt signed Parent National Institutes

into law the National Cancer Institute Act (Pub. Law 75- agency of Health
244; 50 Stat. 559), which established the National Child NCI Shady Grove
Cancer Institute, as a division of the Public Health
agencies Campus
Service.[11][12][13][14]
1940: The first issue of the Journal of the National NCI at NIH
Cancer Institute was published. Bethesda
1944: The United States Congress made the NCI an Campus
operating division of the National Institutes of Health by NCI Frederick
its passage of the Public Health Service Act. Congress Campus
later amended the Public Health Service Act with the
National Cancer Act of 1971, to broaden the scope and Website www.cancer.gov (h
responsibilities of the NCI "in order more effectively to ttps://www.cancer.
carry out the national effort against cancer." gov/)
1955: NCI established the Clinical Trials Cooperative
Footnotes
Group Program, which included several research
[1][2][3][4][5]
networks that conducted cancer clinical research
primarily under the sponsorship of NCI.
 1957: The first cancer, choriocarcinoma, was cured with
chemotherapy at NCI.
1960: NCI began funding government-supported cancer
centers.
1971: President Richard Nixon converted the U.S.
Army's former biological warfare facilities at Fort Detrick,
Maryland, to house research activities on the causes,
treatment, and prevention of cancer.
1971: The National Cancer Act of 1971 declares "war on
cancer," establishes the National Cancer Advisory
Board, and allots additional funding for cancer research. An early wooden sign for the
National Cancer Institute
1975: The Frederick National Laboratory for Cancer
Research opened in Frederick, Maryland, as a Federally
Funded Research and Development Center
1993: The NIH Revitalization Act of 1993 encourages NCI to expand its efforts in prostate
cancer, breast and other cancers which primarily or solely affected women, and authorized
increased appropriations.
1998: Establishes the Office of Cancer Complementary and Alternative Medicine to study
pseudoscientific alternative medicine treatments for cancer
2009: The American Recovery and Reinvestment Act of 2009 provided US$10 billion in
additional funding for the NIH; the NCI received US$1.3 billion from that amount.
2016: The 21st Century Cures Act increased funding for biomedical research. The "Cancer
Moonshot" program promised additional support for cancer research.[15]
On October 17, 2017, Norman Sharpless was sworn in as the 15th director of the National
Cancer Institute. In April 2019, Sharpless left NCI to serve as the acting Commissioner of
Food and Drugs.[16] He returned to the institute in November 2019 as director.[17]

Anti-cancer drug investigations

Alkylating agents Synthetic drugs

Chlorambucil (Leukeran) Hydroxyurea (Hydrea)

(1957)
Cyclophosphamide
(Cytoxan) (1959)
Thiotepa (1959)
Melphalan (Alkeran)
(1959) (IV in 1993)
Streptozotocin (Zanosar)
(1982)
Ifosfamide (Ifex) (1988)
Antimetabolites
Mercaptopurine (1953)
Methotrexate (1953)
Thioguanine (1966)
Cytosine arabinoside (Ara-C) (1969)
Floxuridine (FUDR) (1970)
Fludarabine phosphate (1991)
(1967)
Procarbazine (Matulane)
(1969) Carboplatin
O, P'-DDD (Lysodren,
Cyclophospha Mitotane) (1970)
mide Dacarbazine (DTIC) (1975)
CCNU (Lomustine) (1976)
BCNU (Carmustine) (1977)
Cis-diamminedichloroplatinum (Cisplatin)
(1978)
Mitoxantrone (Novantrone) (1988)
Carboplatin (Paraplatin) (1989)
Levamisole (Ergamisol) (1990)
Hexamethylmelamine (Hexalen) (1990)
All-trans retinoid acid (Vesanoid) (1995)
Porfimer sodium (Photofrin) (1995)
Hormones and steroids
 Pentostatin (1991) DES (1950)
Chlorodeoxyadenosine (1992) Prednisone (1953)
Plant alkaloids and antibiotics Fluoxymesterone (Halotestin) (1958)
Vincristine (Oncovin) Dromostanolone (Drolban) (1961)
(1963) Testolactone (Teslac) (1970)
Actinomycin D Methyl prednisolone
(Cosmegen) (1964) Prednisolone
Vincristine
Mithramycin (Mithracin) Zoladex (1989)
(1970)
Bleomycin (Blenoxane) (1973) Biologicals
Doxorubicin (Adriamycin) (1974)
Mitomycin C (Mutamycin) (1974) Alpha interferon (Intron A, Roferon-A)
(1986)
L-Asparaginase (Elspar) (1978)
BCG (TheraCys, TICE) (1990)
Daunomycin (Cerubidine) (1979)
G-CSF (1991)
VP-16-213 (Etoposide) (1983)
GM-CSF (1991)
VM-26 (Teniposide) (1992)
Interleukin 2 (Proleukin) (1992)
Taxol (Paclitaxel) (1992)

Plant flavonoids

chrysin quercetin galangin naringenin

(1994)
Organization
The NCI is divided into several divisions and centers.[18]

Intramural
Center for Cancer Research (https://ccr.cancer.gov)

The CCR includes approximately 250 internal NCI research groups in Frederick and
Bethesda.[19]

Division of Cancer Epidemiology and Genetics

DCEG is made up of eight branches within the Trans-divisional Research

Program.[20]

Extramural
Division of Cancer Biology

DCB oversees approximately 2000 grants per year in the areas of cancer cell
biology; cancer immunology, hematology, and etiology; DNA and chromosome
aberrations; structural biology and molecular applications; tumor biology and
microenvironment; and tumor metastasis.[21] "Special Research Programs" falling
under the aegis of the DCB include: Physical Sciences-Oncology Network, Cancer
Systems Biology Consortium, Oncology Models Forum, Barrett's Esophagus
Translational Research Network, New Approaches to Synthetic Lethality for Mutant
 KRAS-Dependent Cancers, Molecular and Cellular Characterization of Screen-
Detected Lesions, Fusion Oncoproteins in Childhood Cancers, and Cancer Tissue
Engineering Collaborative.[22]

Division of Cancer Control and Population Sciences

Division of Cancer Prevention
Division of Cancer Treatment and Diagnosis

DCTD supports eight research programs: The Biometric Research Program, The
Cancer Diagnosis Program, The Cancer Imaging Program, The Cancer Therapy
Evaluation Program, The Developmental Therapeutics Program, The Radiation
Research Program, The Translational Research Program, and The Office of Cancer
Complementary and Alternative Medicine.[23]

Division of Extramural Activities

DEA processes and supports the thousands of grant applications NCI receives each
year and compiles reports on the progress of research funded by the NCI's
programs.[24]

Office of the director

Center for Biomedical Informatics and Information Technology
Center for Cancer Genomics

CCG was created in 2011 and is responsible for management of The Cancer
Genome Atlas and cancer genomics initiatives.

Center for Cancer Training

Center for Global Health
Center for Strategic Scientific Initiatives

In the 1990s, the Unconventional Innovation Program was created to integrate

interdisciplinary technology research with biological applications. It was reorganized
in 2004 as the CSSI.[25]

Center to Reduce Cancer Health Disparities

Center for Research Strategy
Coordinating Center for Clinical Trials
Technology Transfer Center

Programs

NCI-designated Cancer Centers

The NCI-designated Cancer Centers are one of the primary arms in the NCI's mission in supporting cancer
research. There are currently 71 so-designated centers; 12 clinical cancer centers, 52 comprehensive cancer
centers, and 7 basic laboratory cancer centers. NCI supports these centers with grant funding in the form of
P30 Cancer Center Support Grants to support shared research resources and interdisciplinary programs.
Additionally, faculty at the cancer centers receive approximately 75% of the grant funding awarded by the
NCI to individual investigators.[9][26]

The NCI cancer centers program was introduced in 1971 with 15 participating institutions.[27]

National Clinical Trials Network

The National Clinical Trials Network (NCTN) was formed in 2014, from the Cooperative Group program
to modernize the existing system to support precision medicine clinical trials. With precision medicine,
many patients must be screened to determine eligibility for treatments in development.

Lead Academic Participating Sites (LAPS) were chosen at 30 academic institutions for their ability to
conduct clinical trials and screen a large number of participants and awarded grants to support the
infrastructure and administration required for clinical trials. Most LAPS grant recipients are also NCI-
designated cancer centers.[10] NCTN also stores surgical tissue from patients in a nationwide network of
tissue banks at various universities.

Developmental Therapeutics Program

The NCI Development Therapeutics Program (DTP) provides services and resources to the academic and
private-sector research communities worldwide to facilitate the discovery and development of new cancer
therapeutic agents.[28]

Under the label "Discovery & Development Services" several services are offered, among them the NCI-
60 human cancer cell line screen and the Molecular Target Program.[29]

In the Molecular Target Program thousands of molecular targets have been measured in the NCI panel of
60 human tumor cell lines. Measurements include protein levels, RNA measurements, mutation status and
enzyme activity levels.[30]

NCI-60 Human Tumor Cell Lines Screen

The evolution of strategies at the NCI illustrates the changes in screening that have resulted from advances
in cancer biology. The Developmental Therapeutics Program (DTP) operates a tiered anti-cancer
compound screening program with the goal of identifying novel chemical leads and biological mechanisms.
The DTP screen is a three phase screen which includes: an initial screen which first involves a single dose
cytotoxicity screen with the 60 cell line assay. Those passing certain thresholds are subjected to a 5 dose
screen of the same 60 cell-line panel to determine a more detailed picture of the biological activity. A
second phase screen establishes the maximum tolerable dosage and involves in vivo examination of tumor
regression using the hollow fiber assay. The third phase of the study is the human tumor xenograft
evaluation.

Active compounds are selected for testing based on several criteria: disease type specificity in the in vitro
assay, unique structure, potency, and demonstration of a unique pattern of cellular cytotoxicity or cytostasis,
indicating a unique mechanism of action or intracellular target.

A high correlation of cytotoxicity with compounds of known biological mechanism is often predictive of
the drugs mechanism of action and thus a tool to aid in the drug development and testing. It also tells if
there is any unique response of the drug which is not similar to any of the standard prototype compounds in
the NCI database.

Leadership
Portrait Director Tenure Notes

Carl January 13, 1938 – July 31,

Voegtlin[31] 1943

Roscoe Roy
August 1, 1943 – July 1, 1947
Spencer

Leonard
Served as the seventh Surgeon General
Andrew July 1, 1947 – April 6, 1948
of the United States from 1948 to 1956.
Scheele

John Roderick
May 15, 1948 – July 1, 1960
Heller

Kenneth Millo July 1, 1960 – November 10,

Endicott 1969

Carl Gwin
July 13, 1970 – May 5, 1972
Baker
Frank Joseph May 5, 1972 – November 1,
Rauscher, Jr. 1976

Arthur Canfield July 29, 1977 – December 31,

Upton 1980

Vincent T. July 9, 1980 – September 1,

DeVita, Jr. 1988

December 22, 1988 – April 1,

Samuel Broder
1995

11th Director, left to become President of

the Case Institute of Health, Science,
Richard D. August 1, 1995 – September and Technology and later Executive
Klausner 30, 2001 Director of Global Health for the Bill &
Melinda Gates Foundation.[32]

12th Director, served from 2001 to 2006

Andrew C. von January 22, 2002 – June 10, before transitioning to a role as
Eschenbach 2006
Commissioner of Food and Drugs.[33][34]
 John E. September 15, 2006 – July 12, 13th Director of the NCI, was nominated
Niederhuber 2010 by President George W. Bush.[35]

Co-winner of the Nobel Prize for studies

Harold Varmus
July 12, 2010 – March 31, of the genetic basis of cancer.[36] He was
2015 director of the National Institutes of
Health from 1993 to 1999.

15th Director of the NCI.[37][38]

Norman E. October 17, 2017 – April 30, Transitioned to acting Commissioner of
Sharpless 2022 Food and Drugs in April 2019 and
returned to NCI in November 2019.[39]

Monica 16th Director of NCI. First woman to hold

October 17, 2022 – Present
Bertagnolli the position. [40]

Notable NCI faculty

Amy Berrington de González, senior investigator and radiation epidemiology branch chief.
Kathryn Zoon, Principal Deputy Director, 2002 to 2004.
Michael B. Sporn was the Chief of the Laboratory of Chemoprevention, 1978 to 1995.
Tom Misteli, NIH Distinguished Investigator and Director of the NCI Center for Cancer
Research
Susan Gottesman
Sankar Adhya
Ira Pastan
Elaine Jaffe
Michael Gottesman
Robert C. Gallo
Michael Potter
Sandra Wolin
Charles J. Sherr
Louis M. Staudt
Gordon Zubrod
 Steven Rosenberg
Alfred Singer, Chief of the Experimental Immunology Branch of the National Cancer Institute
Xiaohong Rose Yang, senior investigator.
Douglas R. Lowy, Chief, Laboratory of Cellular Oncology; NCI Principal Deputy Director,
initial development, characterization, and clinical testing of the preventive virus-like particle-
based HPV vaccines.

Notable people
Susan Shurin, senior adviser
Sudhir Srivastava, chief scientist at Cancer Biomarkers Research Group of the Division of
Cancer Prevention

See also
American Cancer Society Center
caBIG, the Cancer BioInformatics Grid, a National Cancer Institute (USA) initiative to link
cancer researchers and their data
Cancer Information Service (CIS)
European Organisation for Research and Treatment of Cancer (EORTC)
Journal of the National Cancer Institute
National Comprehensive Cancer Network
NCI-designated Cancer Center

Notes and references

1. "Director's Page" (https://www.cancer.gov/director). National Cancer Institute. Retrieved
1 April 2015.
2. "NCI Director Dr. Norman E. Sharpless—Director's Page—Leadership—About NCI" (https://
www.cancer.gov/about-nci/leadership/director). National Cancer Institute. 18 December
2018. Retrieved 1 January 2019.
3. "Dr Norman Edward Sharpless, MD, NIH Enterprise Directory (NED)" (https://ned.nih.gov/se
arch/ViewDetails.aspx?NIHID=2002045786). NED.NIH.gov. Retrieved 2 January 2019.
4. "Visitor Information" (https://www.cancer.gov/about-nci/visit). National Cancer Institute. 1980-
01-01. Retrieved 2 January 2019.
5. NCI's Shady Grove Campus To Open In 2013 (https://nihrecord.nih.gov/newsletters/2010/04
_02_2010/story6.htm). NIH Record. Vol. LXII. 2 April 2010. Retrieved 2 January 2019. "The
change is being made primarily due to the leases expiring at EPN, EPS and a few other
buildings on Executive Blvd. The new buildings would house, in one facility, staff from those
leased sites... NCI will continue to occupy floors 10 and 11 of Bldg. 31's A wing, as well as
much of the 3rd floor, and the NCI director will remain in 31. There are also many staff
members in lab buildings and the Clinical Center on campus and a large presence in
Frederick at Ft. Detrick."
6. Philippidis, Alex (2020-09-21). "Top 50 NIH-Funded Institutions of 2020" (https://www.genen
gnews.com/a-lists/top-50-nih-funded-institutions-of-2020/). GEN - Genetic Engineering and
Biotechnology News. Retrieved 2021-04-25.
7. "NCI-Frederick: NCI-Frederick Home Page" (http://www.ncifcrf.gov). NCIfCrf.gov. Retrieved
18 December 2011.
 8. "Funding Trends" (https://www.cancer.gov/about-nci/budget/fact-book/historical-trends/fundi
ng). National Cancer Institute. 2018-12-20.
9. "NCI-Designated Cancer Centers" (https://www.cancer.gov/research/nci-role/cancer-center
s). National Cancer Institute. 5 April 2012. Retrieved July 26, 2019.
10. "NCI's National Clinical Trials Network" (https://www.cancer.gov/research/areas/clinical-trial
s/nctn). National Cancer Institute. 2014-05-29.
11. "National Cancer Institute Act: Text of the Act of August 5, 1937, creating the National Cancer
Institute and authorizing an appropriation therefor". JNCI Journal of the National Cancer
Institute. 19 (2): 133–137. 1 August 1957. doi:10.1093/jnci/19.2.133 (https://doi.org/10.109
3%2Fjnci%2F19.2.133). ISSN 0027-8874 (https://www.worldcat.org/issn/0027-8874).
PMID 13502712 (https://pubmed.ncbi.nlm.nih.gov/13502712).
12. "Statutes at Large Volume 50 (1937) Table of Contents; VOL. 49 – VOL. 51" (https://web.arch
ive.org/web/20160306050456/http://www.legisworks.org/sal/50/toc50.html). LegisWorks.org.
Archived from the original (http://legisworks.org/sal/50/toc50.html) on 6 March 2016.
Retrieved 1 January 2019.
13. "75th Congress Public Law 244" (https://web.archive.org/web/20160307053937/http://www.l
egisworks.org/congress/75/publaw-244.pdf) (PDF). LegisWorks.org. Archived from the
original (http://legisworks.org/congress/75/publaw-244.pdf) (PDF) on 7 March 2016.
Retrieved 1 January 2019.
14. "Statute 50 Page 559" (https://web.archive.org/web/20160317080953/http://legisworks.org/s
al/50/stats/STATUTE-50-Pg559.pdf) (PDF). LegisWorks.org. Archived from the original (htt
p://legisworks.org/sal/50/stats/STATUTE-50-Pg559.pdf) (PDF) on 17 March 2016. Retrieved
1 January 2019.
15. December 13, 2016—Important Events in NCI History—National Cancer Institute (NCI) (http
s://www.nih.gov/about-nih/what-we-do/nih-almanac/national-cancer-institute-nci#events).
NIH Almanac. 18 October 2017. Retrieved 1 January 2019.
16. Kaplan, Sheila (2019-03-12). "National Cancer Chief, Ned Sharpless, Named F.D.A.'s
Acting Commissioner" (https://www.nytimes.com/2019/03/12/health/fda-ned-sharpless.html).
The New York Times. ISSN 0362-4331 (https://www.worldcat.org/issn/0362-4331).
Retrieved 2019-12-04.
17. Collins, Francis (November 1, 2019). "Statement on the return of Dr. Ned Sharpless as NCI
Director" (https://www.nih.gov/about-nih/who-we-are/nih-director/statements/statement-return
-dr-ned-sharpless-nci-director/). The NIH Director. Retrieved December 3, 2019.
18. "NCI Organization" (https://www.cancer.gov/about-nci/organization#divisions). National
Cancer Institute. 1980-01-01.
19. "About CCR" (https://ccr.cancer.gov/about). 21 July 2014.
20. "DCEG Home" (https://dceg.cancer.gov). Division of Cancer Epidemiology and Genetics –
National Cancer Institute. 1980-01-01.
21. "DCB Research Portfolio" (https://www.cancer.gov/about-nci/organization/dcb/research-portf
olio). National Cancer Institute. 2016-08-08.
22. "Division of Cancer Biology" (https://www.cancer.gov/about-nci/organization/dcb). National
Cancer Institute. 2016-08-08.
23. "About DCTD – DCTD" (https://dctd.cancer.gov/About/default.htm). dctd.cancer.gov.
24. "About NCI Division of Extramural Activities" (https://deainfo.nci.nih.gov/aboutDEA.htm).
deainfo.nci.nih.gov.
25. "History – Center for Strategic Scientific Initiatives (CSSI)" (https://cssi.cancer.gov/about/hist
ory). cssi.cancer.gov.
26. "OCC Homepage – OCCWebApp 2.1.0" (https://cancercenters.cancer.gov/).
cancercenters.cancer.gov.
27. "History of the NCI Cancer Centers Program" (https://www.cancer.gov/research/nci-role/canc
er-centers/history). National Cancer Institute. 2012-08-13.
28. "Welcome to the Developmental Therapeutics Program" (https://dtp.cancer.gov/).
Developmental Therapeutics Program. National Cancer Institute. Retrieved 6 January 2018.
29. "Discovery & Development Services" (https://dtp.cancer.gov/discovery_development/default.
htm). Developmental Therapeutics Program. National Cancer Institute. 26 August 2015.
Retrieved 6 January 2018.
30. "Molecular Targets" (https://dtp.cancer.gov/databases_tools/molecular_target/default.htm).
Developmental Therapeutics Program. National Cancer Institute. 12 May 2015. Retrieved
7 January 2018.
31. "National Cancer Institute (NCI)" (https://www.nih.gov/about-nih/what-we-do/nih-almanac/nat
ional-cancer-institute-nci#director). 7 July 2015.
32. "Dr. Richard D. Klausner Named Executive Director of Global Health for Bill & Melinda
Gates Foundation" (http://www.gatesfoundation.org/Media-Center/Press-Releases/2002/05/
Dr-Richard-D-Klausner-Executive-Director-of-Global-Health).
33. U.S. Congress (7 December 2006). "Executive Session" (http://frwebgate.access.gpo.gov/cg
i-bin/getpage.cgi?dbname=2006_record&page=S11404&position=all). Congressional
Record. 152 (134): S11404–29, S11447–51. Retrieved 2006-12-12.
34. "U.S. Senate: U.S. Senate Roll Call Votes 109th Congress – 2nd Session" (https://www.sen
ate.gov/legislative/LIS/roll_call_lists/roll_call_vote_cfm.cfm?congress=109&session=2&vote
=00274). www.senate.gov.
35. "Emergent Biosolutions – Board of Directors bio" (http://investors.emergentbiosolutions.com/
phoenix.zhtml?c=202582&p=irol-govBio&ID=203684). Retrieved 2013-12-06.
36. "Director's Page – National Cancer Institute (Archive)" (https://wayback.archive-it.org/5574/2
0150331220844/http://www.cancer.gov/aboutnci/director/messages/harold-varmus-resignati
on). Cancer.gov. Archived from the original on 2015-03-31. Retrieved 2015-04-02.
37. "NCI Director Dr. Norman E. Sharpless—Director's Page—Leadership—About NCI" (https://
www.cancer.gov/about-nci/leadership/director). National Cancer Institute. 18 December
2018. Retrieved 1 January 2019.
38. "Dr Norman Edward Sharpless, MD, NIH Enterprise Directory (NED)" (https://ned.nih.gov/se
arch/ViewDetails.aspx?NIHID=2002045786). NED.NIH.gov. Retrieved 2 January 2019.
39. "NCI Director Dr. Norman E. Sharpless" (https://www.cancer.gov/about-nci/leadership/direct
or). National Cancer Institute. 2017-10-17. Retrieved 2020-02-12.
40. "Monica Bertagnolli becomes NCI director - NCI" (https://www.cancer.gov/news-events/pres
s-releases/2022/bertagnolli-nci-director). www.cancer.gov. 2022-10-03. Retrieved
2022-10-21.

General references
National Cancer Institute (https://web.archive.org/web/20100527085250/http://www.cancer.g
ov/aboutnci/director-announced?cid=B_ND) Retrieved 11 June 2010.
"NCI MISSION STATEMENT" (https://www.cancer.gov/aboutnci/overview/mission). National
Cancer Institute. Retrieved 18 August 2004.
"THE NATIONAL CANCER ACT OF 1971" (https://web.archive.org/web/20041018173821/h
ttp://www3.cancer.gov/legis/1971canc.html). National Cancer Institute. Retrieved 18 August
2004.
 Developmental Therapeutics Program (DTP) (https://web.archive.org/web/2012062705101
1/http://dctd.cancer.gov/ProgramPages/dtp/default.htm)

External links
Official website (https://www.cancer.gov/)
NCI (https://www.usaspending.gov/federal_account/075-0849) account on
USAspending.gov
NCI Dictionaries (https://www.cancer.gov/publications/dictionaries): NCI Dictionary of
Cancer Terms (utilizing non-technical language) • NCI Dictionary of Genetics Terms (for
healthcare professionals) • NCI Drug Dictionary (includes links for potential clinical trials)
NCI (https://history.nih.gov/display/history/NCI) in A Short History of the National Institutes of
Health, an online exhibit by the Office of NIH History
Important Events in NCI History (https://www.nih.gov/about-nih/what-we-do/nih-almanac/nati
onal-cancer-institute-nci#events) from the NIH Almanac
Major NCI Milestones (https://www.cancer.gov/PublishedContent/Images/images/infographic
s/major-nci-milestones-enlarge.__v1100247949.gif) infographic

Retrieved from "https://en.wikipedia.org/w/index.php?title=National_Cancer_Institute&oldid=1155954560"